[{"Assets_0_Q3_USD":435235000.0,"CommonStockDividendsPerShareDeclared_3_Q3_USD":0.0,"CommonStockSharesConverted_0_Q3_shares":31270573.0,"CommonStockSharesOutstanding_0_Q3_shares":31270573.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":-23172000.0,"NetIncomeLossConverted_1_Q3_USD":-43497000.0,"NetIncomeLossConverted_3_Q3_USD":-180996000.0,"StockholdersEquity_0_Q3_USD":-168443000.0,"EarningsPerShareBasic_1_Q3_USD":-10.71,"EarningsPerShareBasic_3_Q3_USD":-16.38,"Ticker":"ALLO","CIK":"1737287","name":"ALLOGENE THERAPEUTICS, INC.","OfficialName":"Allogene Therapeutics Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1134878416.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20181121"}]